New drug can help stop certain breast cancer tumours early, trial shows
It is the first worldwide study to show that using blood tests to find early signs of cancer resistance to treatment helps patients, scientists say.
The study looked at patients who had hormone-positive, HER2-negative breast cancer, which is about 70% of cases.
The results of the Serena-6 trial represent more than a clinical milestone, they represent a transformational shift in how we approach precision medicine Professor Kristian Helin, Institute of Cancer Research
Results showed patients given camizestrant reduced their chances of cancer progression by 56%, compared with just standard therapies.
Doctors used a simple blood test to spot changes in the cancer's DNA that show whether current treatments might soon stop working.
When they found these signs, some patients were given camizestrant, while others stayed on their usual treatment.
Those on camizestrant had their cancer stay the same and not get worse for much longer, 16 months on average, compared with about nine months for the others.
The drug was safe for most patients but 1% stopped taking it because of side effects.
More than 3,000 patients from 23 countries took part in the study, which was funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research in London.
This study is a clear example of how blood tests are starting to transform cancer treatment Dr Catherine Elliott, Cancer Research UK
Co-principal investigator Professor Nick Turner, group leader in molecular oncology at The Institute of Cancer Research, London, said the drug is 'a pivotal moment in breast cancer care'.
Professor Kristian Helin, chief executive of The Institute of Cancer Research said: 'The results of the Serena-6 trial represent more than a clinical milestone, they represent a transformational shift in how we approach precision medicine.'
About 55,000 women are diagnosed with breast cancer in the UK every year and 11,500 will die from the disease, The Institute of Cancer Research said.
The Serena-6 trial results were to be presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on Sunday.
Dr Catherine Elliott, director of research at Cancer Research UK, said: 'This study is a clear example of how blood tests are starting to transform cancer treatment.
'By tracking tiny traces of tumour DNA in the blood, researchers were able to spot early signs of treatment resistance and switch therapies before cancer had a chance to grow.
'It shows how circulating tumour DNA, or ctDNA, could help doctors make smarter, more timely treatment decisions.
'This approach could become an important part of how we personalise care for people with advanced breast cancer.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
18 hours ago
- Daily Mail
Top GP urges men to know the signs of penis cancer... as it becomes a bigger killer than testicular cancer
A leading GP has warned men to watch out for the silent signs of a deadly cancer that kills hundreds each year, overtaking testicular cancer deaths. Penile cancer is notoriously hard to spot because symptoms can easily be mistaken for less serious problems, which men are often too embarrassed to talk about. As a result, late diagnosis is becoming increasingly common, with many men ignoring early warning signs—which could result in amputation. Of men diagnosed with penile cancer early, more than 90 per cent go on to survive at least five years after diagnosis. However, the outlook for men with the most advanced cancer where it has spread to other parts of the body is bleak: no men in this group are expected to survive for five years after their diagnosis. B NHS GP Dr Mark Porter says men could help reduce their risk of a late-stage diagnosis by watching out for the little known signs of the deadly disease which may not only save their lives, but their penises too. According to Cancer Research UK, 63 per cent of penile cancer cases in the UK are preventable. Writing for The Times he said whilst cancer can develop anywhere on the penis, most penile cancers affect the foreskin or the head (glans) of the penis. Common early symptoms include discolouration—which is often red or bluish-brown—a persistent rash or sore that lasts longer than a month, and an obvious lump or growth either on the penis or surrounding groin area. Other red-flag warning signs include bleeding, abnormal discharge and phimosis—where it becomes difficult to retract the foreskin. However, he added these symptoms are not always a cause for serious concern and are usually the result of an infection like thrush or inflammatory conditions. It is also not uncommon for men to experience bleeding after trauma to the sensitive area which can tear the frenulum, the band of tissue that connects the foreskin to the head of the penis. This can happen after intercourse, he added. Even so, Dr Porter urged men not to dismiss any abnormal changes to the area, however slight, and to contact their GP if they are concerned. 'There is a good chance the result won't be as bad as you feared—but that doesn't mean it's okay to put off that appointment,' he said. Whilst penile cancer is rare and typically affects middle-aged men, it can develop much sooner, making early diagnosis crucial. 'The other major advantage of early diagnosis is that often it means treatment is less invasive,' the GP explained. According to the NHS, treatment for early cancer is usually non-surgical, including chemotherapy creams such as 5 fluorouracil and laser therapy through which suspicious lesions are 'burnt off'. However, if the cancer is found later, perhaps as a result of patients putting off seeking help, treatment is a lot more aggressive. This can include removing the top layer of skin from the head of the penis, cutting out lymph nodes—which help the body to fight off infection—and even amputation. A full amputation, known as a penectomy, also involves having to have a new outlet for the bladder made between the anus and scrotum. But, the NHS warns, any surgery is likely to affect how a patient's penis looks. Chemotherapy, radiotherapy and immunotherapy can all also be used to help shrink tumours and reduce the risk of the cancer spreading further. Reconstructive surgery is an option for men who have had to have their penis removed, using skin and muscles from other parts of the body to make a fully functioning penis. Whilst any man can get penile cancer certain factors can increase an individual man's risk of developing the disease. According to the NHS around half of all penile cancers are caused by certain types of HPV which affect the genital area. The virus—medically known as human papillomavirus—can be spread via skin-to-skin contact of the genital area, vaginal, anal or oral sex and sharing sex toys. As such, according to Cancer Research UK, 63 per cent of penile cancer cases are preventable. Smoking also increases the risk of developing the disease and those who are immunocompromised due to conditions like HIV are also more likely to get penile cancer. Dr Porter added: 'Circumcision as a child or teenager offers protection against the disease as it reduced exposure to secretions known as smegma produced by the foreskin.' A six-year study was launched back in 2021 to ascertain how successful a new form of immunotherapy—called cemiplmab—is at treating penile cancer that has spread. The Epic study, led by Professor Amit Bahl a urology professor at the University of Bristol, is still ongoing but if initial findings can be upheld experts believe it could help prolong the lives of men with advanced penile cancer. Around one in 400 men in the UK are diagnosed with penile cancer each year, with the disease killing twice as many men as testicular cancer.
Daily Mirror
3 days ago
- Daily Mirror
Breakthrough in breast cancer research could stop the disease from spreading
The discovery offers new hope in the fight against breast cancer, as it could detect and stop the spread of the disease before it becomes incurable Scientists have achieved a significant breakthrough in the battle against breast cancer by dismantling the very components that enable the deadly disease to metastasise. Researchers have discovered that cancer alters the metabolism of certain immune cells, causing them to release a metabolite known as uracil, which aids in constructing a 'scaffold' within distant organs, facilitating the growth of secondary tumours. By inhibiting the enzyme uridine phosphorylase-1 (UPP1), responsible for producing uracil, scientists were able to prevent this 'scaffold' from forming in mice and rejuvenated the immune system's capacity to eliminate secondary cancer cells, thereby thwarting metastasis. This groundbreaking work was carried out in the laboratories of Professor Jim Norman and Professor Karen Blyth at the Cancer Research UK Scotland Institute and the University of Glasgow. This discovery paves the way for potentially potent new methods to combat cancer – identifying uracil in the bloodstream could signal early indications of cancer metastasis, while impeding UPP1 with medication could halt its progression before it even begins. The study's lead author, Dr Cassie Clarke, from the Cancer Research UK Scotland Institute and University of Glasgow, said: "This study represents a major shift in how we think about preventing the spread of breast cancer. By targeting these metabolic changes as early as possible we could stop the cancer progressing and save lives." Published in Embo Reports, the research indicates that crucial metabolic alterations take place prior to the dissemination of cancer, presenting an essential opportunity for intervention. Identifying these alterations at an early stage could enable treatments to prevent cancer cells from migrating throughout the body and establishing tumours in different locations. Dr Catherine Elliott, Cancer Research UK's director of research, explained: "Discoveries in cancer research have made huge strides in making breast cancer a far more treatable disease than ever before. However, metastasis - when cancer spreads - is a major factor in breast cancer becoming harder to treat especially if the cancer returns months or even many years later. "This discovery gives us new hope for detecting and stopping metastasis early and ensuring people have many more years with their families and loved ones." With approximately 56,800 people receiving a breast cancer diagnosis in the United Kingdom annually and roughly 11,300 people dying from it each year, discovering innovative approaches to combat it remains crucial. Due to research breakthroughs, breast cancer has evolved into a significantly more manageable illness, yet when it metastasises to different parts of the body, effective control becomes increasingly challenging. Comprehending the mechanisms behind breast cancer's spread is essential to preventing the disease from becoming uncontrollable with existing treatments. The research team is now delving deeper into precisely how UPP1 alters immune cell behaviour, examining the function of immune cell metabolism in early breast cancer development, and evaluating the potential of medications that inhibit immune cell metabolism to prevent cancer onset. Simon Vincent, the chief scientific officer at Breast Cancer Now, said: "This is an exciting piece of joint research that expands our understanding of how secondary breast cancer develops. "The researchers discovered that high levels of a protein called UPP1 may make some cancers, including breast cancer, more likely to spread to other parts of the body, where the disease becomes incurable. "In mice, targeting the UPP1 protein before secondary breast cancer developed led to fewer secondary breast tumours and a boosted immune response in the lungs. "Now we need more research to see if this new insight can be turned into new drugs that stop secondary breast cancer, and potentially other secondary cancers, in their tracks. With around 61,000 people living with secondary breast cancer in the UK, research like this is vital."
Daily Record
4 days ago
- Daily Record
Scots scientists make breast cancer discovery that could stop disease spreading
The discovery could offer patients a vital new window for cancer intervention. A team of Scots scientists have made a groundbreaking new discovery which could help stop the spread of breast cancer - one of the leading causes of death from the disease. Under the research, conducted by experts at the Cancer Research UK Scotland Institute and the University of Glasgow, patients could be offered a vital new window for intervention. The study focused on how breast cancer changes the immune system so it can't tackle cancer cells as they begin to spread. The researchers found that cancer changes the metabolism (the way cells make and use energy) of specific immune cells resulting in them releasing a prominent metabolite called uracil. Uracil is a molecule key to essential processes in the body which was found to help distant organs build a 'scaffold' to grow secondary tumours elsewhere in the body. By blocking an enzyme called uridine phosphorylase-1 (UPP1), which produces uracil, the scientists were able to stop this scaffold forming in mice and restore the ability of the immune system to kill secondary cancer cells to prevent metastasis. It opens the door to new potentially powerful new tools to tackle cancer - detecting uracil in the blood could help spot early signs of cancer spread then blocking UPP1 with drugs could stop the spread before it starts. The study was conducted in the labs of Professor Jim Norman and Professor Karen Blyth at the Cancer Research UK Scotland Institute and the University of Glasgow. Study lead Dr Cassie Clarke, of the Cancer Research UK Scotland Institute and University of Glasgow, said: "This study represents a major shift in how we think about preventing the spread of breast cancer. By targeting these metabolic changes as early as possible we could stop the cancer progressing and save lives.' Every year, around 56,800 people are diagnosed with breast cancer in United Kingdom. Around 11,300 people sadly lose their lives to the disease. Thanks to research, breast cancer has become a far more treatable disease, but once it spreads to other areas within the body it becomes harder to control effectively. Understanding how and why breast cancer spreads is key to preventing the disease becoming unmanageable with current therapies. Cancer Research UK's Director of Research, Dr Catherine Elliott, said: ' Discoveries in cancer research have made huge strides in making breast cancer a far more treatable disease than ever before. 'However, metastasis - when cancer spreads - is a major factor in breast cancer becoming harder to treat especially if the cancer returns months or even many years later. 'This discovery gives us new hope for detecting and stopping metastasis early and ensuring people have many more years with their families and loved ones.' Simon Vincent, chief scientific officer at Breast Cancer Now, said: 'This is an exciting piece of joint research that expands our understanding of how secondary breast cancer develops. 'The researchers discovered that high levels of a protein called UPP1 may make some cancers, including breast cancer, more likely to spread to other parts of the body, where the disease becomes incurable. 'In mice, targeting the UPP1 protein before secondary breast cancer developed led to fewer secondary breast tumours and a boosted immune response in the lungs. 'Now we need more research to see if this new insight can be turned into new drugs that stop secondary breast cancer, and potentially other secondary cancers, in their tracks. With around 61,000 people living with secondary breast cancer in the UK, research like this is vital."
